Results 91 to 100 of about 1,848 (184)

Outcomes of transition from selexipag to parenteral prostacyclin analogues in patients with pulmonary arterial hypertension. [PDF]

ERJ Open Res
AlEissa E, Kolkman L, Kapasi A, Peng D, Provencher S, Brunner N, Swiston J.   +6 more
europepmc   +1 more source

Indirect Treatment Comparison of Riociguat Replacement Therapy and Selexipag Add-on Therapy in Patients With Pulmonary Arterial Hypertension: Results From a Systematic Review. [PDF]

Rev Cardiovasc Med
An JE, Cho J, Kim MJ, Lee AY, Sim WJ, Hong GU, Lee SH, Kim DS, Yi SY, Lee KM, Yu SY.   +10 more
europepmc   +1 more source

Upfront triple combination therapy with selexipag: insights from a real world cohort in Chinese patients with pulmonary arterial hypertension. [PDF]

Front Cardiovasc Med
Cui X, Hu X, Qin X, Li H, Xu X, Liu H, Ji Q.   +6 more
europepmc   +1 more source

Oral Prostacyclin Pathway Agents Used in PAH: A Targeted Literature Review

ClinicoEconomics and Outcomes Research
Charles D Burger,1 Yuen Tsang,2 Marie Chivers,3 Riya Vijay Vekaria,3 Gurinderpal Doad,2,4 Nikki Atkins,3 Sumeet Panjabi2,4 1Division of Pulmonary Medicine, Mayo Clinic Florida, Jacksonville, FL, USA; 2Janssen Scientific Affiars, Titusville, NJ, USA ...
Burger CD, Tsang Y, Chivers M, Vekaria RV, Doad G, Atkins N, Panjabi S   +6 more
doaj  

Experience with selexipag in triple therapy for pulmonary arterial hypertension in Chinese children. [PDF]

BMC Pediatr
Li M, Wang Y, Hu X, Zhao H, Lu W, Ji Y, Cui X.   +6 more
europepmc   +1 more source

Reply to the Letter to the Editor: "Risk Trajectory and Right Ventricular Adaptation in Selexipag- Based Triple Therapy for Pulmonary Arterial Hypertension". [PDF]

Anatol J Cardiol
Kaymaz C, Tokgöz HC.
europepmc   +1 more source

Practical Considerations for Managing Transitions from Parenteral Prostacyclins to Oral Selexipag in Pulmonary Arterial Hypertension. [PDF]

Pulm Ther
Elwing JM, Benninger C, Strachan P, Triyasakorn K, Choren M, Timms BK, Reed L.   +6 more
europepmc   +1 more source

Risk Trajectory and Right Ventricular Adaptation in Selexipag-Based Triple Therapy for Pulmonary Arterial Hypertension. [PDF]

Anatol J Cardiol
Mahida K, Jagtap SR.
europepmc   +1 more source

Editorial Comment: "Could We Maintain the Initial Efficacy of Triple Sequential Combination Therapies with Selexipag Against Progressive Deterioration Risk in Patients with Pulmonary Arterial Hypertension: Insights from a Single-Centre Study". [PDF]

Anatol J Cardiol
Badagliacca R, Tello K.
europepmc   +1 more source

Correction: Sotatercept Versus Selexipag in Severe Pulmonary Arterial Hypertension: An Indirect Comparison of Efficacy Based on an Artificial-Intelligence Method That Reconstructed Patient-Level Data From Three Randomized Trials. [PDF]

Cureus
Messori A, Brunoro R, Paolì MG, Rivano M.   +3 more
europepmc   +1 more source